Generalised Anxiety Disorder (GAD)
Summary
Generalised Anxiety Disorder (GAD) is characterised by excessive, persistent worry about multiple life domains (work, health, finances, family) occurring on most days for at least 6 months. The anxiety is difficult to control and is associated with physical symptoms such as muscle tension, restlessness, fatigue, and sleep disturbance. GAD is common (lifetime prevalence 5-6%) and often comorbid with depression and other anxiety disorders. Treatment includes psychological therapies (CBT, applied relaxation) and pharmacotherapy (SSRIs as first-line), with a stepped care approach based on severity.
Key Facts
- Definition: Excessive worry about multiple domains, most days, for ≥6 months
- Prevalence: Lifetime 5-6%; 12-month prevalence 2-3%
- Sex Ratio: Female:Male 2:1
- Peak Age: 30-45 years; can occur at any age
- First-Line Treatment: CBT or SSRI (sertraline)
- Assessment Tool: GAD-7 scale (screening and monitoring)
Clinical Pearls
"Free-Floating Anxiety": Unlike specific phobias or panic disorder, GAD involves worry about "everything" — patients often describe feeling constantly "on edge" without a specific trigger.
GAD-7 for Screening and Monitoring: The GAD-7 is a validated 7-item questionnaire. Score ≥10 suggests moderate-severe anxiety warranting treatment. It's also excellent for monitoring response to therapy.
Comorbidity is the Rule, Not Exception: 60-90% have comorbid psychiatric conditions (depression, other anxiety disorders, substance use). Always screen for depression (PHQ-9) in patients with GAD.
Why This Matters Clinically
GAD is common in primary care and significantly impacts quality of life, work productivity, and physical health (e.g., increased cardiovascular risk). Early recognition and appropriate stepped care can lead to significant improvement in most patients.
Incidence & Prevalence
- Lifetime Prevalence: 5-6%
- 12-Month Prevalence: 2-3%
- Primary Care: One of the most common mental health presentations
- Onset: Can occur at any age; mean onset mid-20s to 30s
Demographics
| Factor | Details |
|---|---|
| Age | Peak onset 30-45 years; can occur childhood to late life |
| Sex | Female:Male 2:1 |
| Ethnicity | Similar rates across ethnic groups |
| Socioeconomic | Higher in lower SES groups |
Risk Factors
Genetic:
- Heritability ~30%
- Family history of anxiety or mood disorders
Environmental:
| Factor | Association |
|---|---|
| Childhood adversity | Trauma, neglect, abuse |
| Stressful life events | Loss, chronic stress |
| Chronic medical illness | Increases anxiety risk |
| Personality | Neuroticism, behavioral inhibition |
| Female sex | 2x risk |
Comorbidity
| Condition | Prevalence in GAD |
|---|---|
| Major depressive disorder | 60-70% |
| Other anxiety disorders | 50-60% |
| Substance use disorders | 20-30% |
| Chronic pain | Common |
| Cardiovascular disease | Increased risk |
Mechanism
Neurobiological:
Step 1: Threat Detection (Amygdala)
- Hyperactive amygdala
- Exaggerated threat perception
- Increased vigilance
Step 2: Reduced Prefrontal Inhibition
- Prefrontal cortex normally inhibits amygdala
- Reduced connectivity in GAD
- Impaired emotion regulation
Step 3: Neurotransmitter Dysregulation
- GABA: Reduced inhibitory tone
- Serotonin: Dysregulated
- Noradrenaline: Hyperactivity
Psychological:
- Intolerance of Uncertainty: Core cognitive feature; worry as attempt to control uncertainty
- Worry as Avoidance: Cognitive avoidance of feared imagery
- Safety Behaviours: Reassurance-seeking, avoidance maintain anxiety
Classification (DSM-5)
Diagnostic Criteria:
- Excessive anxiety and worry about multiple events/activities
- Most days for ≥6 months
- Difficulty controlling worry
- ≥3 of: restlessness, fatigue, concentration difficulty, irritability, muscle tension, sleep disturbance
- Significant distress or functional impairment
- Not due to substances or medical condition
- Not better explained by another mental disorder
Symptoms
Psychological:
Physical (Somatic):
Signs
Red Flags
[!CAUTION] Red Flags — Require urgent assessment:
- Suicidal ideation or plans
- Psychotic features (hallucinations, delusions)
- Severe self-neglect
- Sudden onset with prominent physical symptoms (rule out medical causes: thyroid, cardiac, substances)
- Severe functional impairment (cannot work, care for self/family)
Structured Approach
Mental State Examination:
- Appearance: May appear tense, restless
- Behaviour: Fidgeting, reassurance-seeking
- Speech: May be pressured or hesitant
- Mood: Anxious (self-reported)
- Affect: Anxious, may be tearful
- Thought: Preoccupation with worries; no psychotic content
- Cognition: May have difficulty concentrating
- Insight: Usually preserved
Physical Examination:
- Vital signs (tachycardia, elevated BP when anxious)
- Thyroid examination (exclude hyperthyroidism)
- Neurological (exclude tremor causes)
- General examination (exclude medical causes)
Assessment Tools
| Tool | Purpose | Scoring |
|---|---|---|
| GAD-7 | Screen and monitor GAD severity | 0-4 minimal, 5-9 mild, 10-14 moderate, 15-21 severe |
| PHQ-9 | Screen for comorbid depression | ≥10 suggests depression |
| AUDIT-C | Screen for alcohol misuse | Common comorbidity |
| GAD-2 | Ultra-brief screen (first 2 items of GAD-7) | ≥3 warrants full GAD-7 |
First-Line
Primary Purpose: Rule out medical causes of anxiety
| Test | Purpose |
|---|---|
| TFTs | Exclude hyperthyroidism |
| FBC | Exclude anaemia |
| Glucose | Exclude hypoglycaemia |
| ECG | If palpitations (exclude arrhythmia) |
| Urine drug screen | If substance use suspected |
Laboratory Tests
| Test | When to Consider |
|---|---|
| Calcium, magnesium | If specific indication |
| Cortisol | If Cushing's suspected |
| Caffeine intake | History (often overlooked cause) |
Imaging
- Not routinely indicated
- Brain MRI only if focal neurological signs or atypical presentation
Diagnostic Criteria (DSM-5)
For GAD diagnosis, ALL of the following:
- Excessive anxiety/worry, multiple events, most days, ≥6 months
- Difficulty controlling worry
- ≥3 associated symptoms (restlessness, fatigue, concentration, irritability, muscle tension, sleep)
- Clinically significant distress or impairment
- Not attributable to substances or medical condition
- Not better explained by another psychiatric disorder
Management Algorithm
GAD MANAGEMENT (NICE Stepped Care)
↓
┌─────────────────────────────────────────────────────┐
│ STEP 1: ALL PATIENTS │
│ │
│ • Psychoeducation (explain anxiety, course, Rx) │
│ • Lifestyle advice (exercise, sleep, reduce caffeine)│
│ • Active monitoring (watchful waiting) │
│ • Self-help resources (NHS apps, books) │
└─────────────────────────────────────────────────────┘
↓
┌─────────────────────────────────────────────────────┐
│ STEP 2: MILD-MODERATE GAD │
│ │
│ Low-intensity psychological intervention: │
│ • Guided self-help (CBT-based, 6+ weeks) │
│ • Psychoeducation groups │
│ • Computerized CBT (e.g., Beating the Blues) │
│ │
│ Consider SSRI if patient prefers medication │
└─────────────────────────────────────────────────────┘
↓
┌─────────────────────────────────────────────────────┐
│ STEP 3: MODERATE-SEVERE / STEP 2 FAILED │
│ │
│ High-intensity psychological therapy: │
│ • CBT (typically 12-16 sessions) │
│ • Applied relaxation │
│ │
│ OR Pharmacotherapy: │
│ FIRST-LINE: SSRI │
│ • Sertraline 50mg → up to 200mg │
│ • Other: Escitalopram, paroxetine │
│ • Trial 8-12 weeks at adequate dose │
│ │
│ SECOND-LINE (if SSRI fails): │
│ • SNRI: Duloxetine 60-120mg or Venlafaxine 75-225mg │
│ • Pregabalin 150-600mg/day │
│ │
│ Consider combination: CBT + medication │
└─────────────────────────────────────────────────────┘
↓
┌─────────────────────────────────────────────────────┐
│ STEP 4: TREATMENT-RESISTANT / COMPLEX │
│ │
│ • Refer to specialist (psychiatry, CMHT) │
│ • Review diagnosis and comorbidities │
│ • Consider: │
│ - Augmentation strategies │
│ - Quetiapine (off-label) │
│ - Buspirone │
│ - Intensive psychological therapy │
│ │
│ ⚠ BENZODIAZEPINES: Short-term only (<2-4 weeks) │
│ for crisis; NOT for ongoing use (dependence) │
└─────────────────────────────────────────────────────┘
Psychological Therapies
Cognitive Behavioural Therapy (CBT):
- Most evidence-based therapy for GAD
- Typically 12-16 sessions
- Challenges unhelpful thinking patterns
- Behavioural experiments, graded exposure
- Worry time, stimulus control
Applied Relaxation:
- Effective alternative to CBT
- Progressive muscle relaxation
- Applied to anxiety-provoking situations
Pharmacotherapy
| Drug | Starting Dose | Target Dose | Notes |
|---|---|---|---|
| Sertraline | 50mg OD | 50-200mg | NICE first-line |
| Escitalopram | 5-10mg | 10-20mg | Well-tolerated |
| Duloxetine | 30mg OD | 60-120mg | SNRI; also for pain |
| Venlafaxine | 37.5mg OD | 75-225mg | SNRI; monitor BP |
| Pregabalin | 75mg BD | 150-600mg/day | Licensed for GAD; potential for dependence |
| Buspirone | 5mg TDS | 15-45mg/day | Delayed onset (2-4 weeks) |
Important Prescribing Notes
- SSRIs may initially worsen anxiety: Warn patients; consider low starting dose
- Takes 4-6 weeks for effect: Trial adequate dose for 8-12 weeks before switching
- Continue for 12 months minimum after remission
- Benzodiazepines: Short-term crisis use ONLY (max 2-4 weeks); avoid in GAD
Untreated GAD
| Complication | Notes |
|---|---|
| Major depression | 60-70% develop comorbid depression |
| Substance misuse | Self-medication with alcohol, drugs |
| Functional impairment | Work, relationships, social |
| Reduced quality of life | Significant impact |
| Cardiovascular disease | Increased risk |
| Somatic complaints | Frequent healthcare utilization |
Treatment-Related
- SSRI side effects (nausea, sexual dysfunction, headache, initially worsened anxiety)
- SNRI: As above + elevated BP (monitor with venlafaxine)
- Pregabalin: Dizziness, sedation, weight gain, dependence risk
- Benzodiazepines: Dependence, cognitive impairment, falls
Natural History
GAD tends to be a chronic, fluctuating condition. Without treatment, symptoms often persist for years, with waxing and waning course related to life stressors. With appropriate treatment, most patients improve significantly.
Outcomes with Treatment
| Variable | Outcome |
|---|---|
| CBT | 50-60% response; durable benefits |
| SSRI/SNRI | 50-60% response |
| Combination (CBT + medication) | May be superior for severe cases |
| Relapse rate | 20-40% after stopping treatment |
Prognostic Factors
Good Prognosis:
- Shorter duration before treatment
- No comorbid depression or substance use
- Good response to initial treatment
- Good social support
- Engagement with psychological therapy
Poorer Prognosis:
- Comorbid depression or substance misuse
- Personality disorder
- Childhood adversity
- Chronic course before treatment
- Poor treatment adherence
Key Guidelines
-
NICE CG113: Generalised Anxiety Disorder (2011, updated 2019) — Stepped care model; CBT and SSRIs as first-line; pregabalin for resistant cases.
-
BAP Guidelines (2014) — British Association for Psychopharmacology; detailed pharmacotherapy guidance.
Landmark Trials
NICE Guideline Systematic Reviews — Foundation for stepped care
- Meta-analyses of CBT, SSRIs, SNRIs, pregabalin
- Key finding: CBT and SSRIs equally effective; pregabalin effective second-line
- Clinical Impact: Established stepped care model
Baldwin et al. (2014) — World Federation guidelines
- International consensus on GAD pharmacotherapy
- Key finding: SSRIs first-line, SNRIs and pregabalin second-line
- Clinical Impact: Global standardization of approach
Evidence Strength
| Intervention | Level | Key Evidence |
|---|---|---|
| CBT | 1a | Cochrane reviews, NICE |
| SSRI (sertraline) | 1a | Meta-analyses |
| SNRI (duloxetine, venlafaxine) | 1a | RCTs |
| Pregabalin | 1a | RCTs (licensed for GAD) |
| Applied relaxation | 1b | RCTs |
What is Generalised Anxiety Disorder?
Generalised Anxiety Disorder (GAD) is a condition where you feel anxious and worried most of the time, about many different things — work, health, family, money, even small everyday matters. This worry is hard to control and goes on for months or longer. It's not the same as normal stress that comes and goes; GAD is persistent and can significantly affect your daily life.
Why does it matter?
Constant anxiety is exhausting and can affect your sleep, concentration, relationships, and work. It often comes with physical symptoms like muscle tension, headaches, and tiredness. The good news is that GAD is very treatable, and most people improve significantly with the right help.
How is it treated?
There are two main approaches, often used together:
-
Talking therapy (CBT): Cognitive Behavioural Therapy helps you understand and change the thinking patterns that keep anxiety going. It's highly effective and the benefits last long after treatment ends.
-
Medication: SSRI antidepressants (like sertraline) are commonly used and effective. They take 4-6 weeks to work fully. You may need to take them for 12 months or more.
-
Self-help: Guided self-help programs, apps (like NHS-approved anxiety apps), and books can be helpful, especially for milder symptoms.
-
Lifestyle changes: Regular exercise, good sleep habits, reducing caffeine, and relaxation techniques all help.
What to expect
- Improvement usually takes several weeks, whether using therapy or medication
- You may need to try different approaches before finding what works best for you
- Many people recover fully, though some have periods of anxiety that return during stressful times
- Learning coping skills helps prevent future episodes
When to seek help
See a doctor if:
- Anxiety is affecting your daily life, work, or relationships
- You're using alcohol or drugs to cope with anxiety
- You're feeling hopeless or having thoughts of harming yourself
- You have panic attacks or physical symptoms that concern you
Primary Guidelines
- National Institute for Health and Care Excellence. Generalised anxiety disorder and panic disorder in adults: management (CG113). 2011, updated 2019. nice.org.uk/guidance/cg113
Key Studies
-
Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28(5):403-439. PMID: 24713617
-
Cuijpers P, Sijbrandij M, Koole S, et al. Psychological treatment of generalized anxiety disorder: a meta-analysis. Clin Psychol Rev. 2014;34(2):130-140. PMID: 24487344
-
Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092-1097. PMID: 16717171
Further Resources
- Anxiety UK: anxietyuk.org.uk
- Mind: mind.org.uk
- NICE CKS: cks.nice.org.uk
Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate guidelines and specialists for patient care.